Safety and Effectiveness of Highly Active Antiretroviral Therapy in Treatment-Naïve HIV Patients: Preliminary Findings of a Cohort Event Monitoring Study in Belarus

Drug Safety

Volumn 38, Issue 4, 2015, Pages 365-372

  Setkina, Svetlana ^a   Dotsenko, Marina ^b   Bondar, Sviatlana ^c   Charnysh, Iryna ^a   Kuchko, Alla ^a   Kaznacheeva, Alena ^d   Kozorez, Elena ^d   Dodaleva, Alena ^e   Rossa, Natalia ^f  

^a Republic Clinical Pharmacological Laboratory   (Belarus)

^b Infectious Disease Department of Belarus Medicinal University   (Belarus)

^c Soligorsk Regional Infectious Hospital   (Belarus)

^d Gomel Regional Clinical Hospital   (Belarus)

^e Zhlobin Central Regional Hospital   (Belarus)

^f Minsk Infectious Hospital   (Belarus)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ADULT; ADVERSE EFFECTS; BELARUS; CD4 LYMPHOCYTE COUNT; DRUG SURVEILLANCE PROGRAM; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV INFECTIONS; HUMAN; MALE; MIDDLE AGED; YOUNG ADULT;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; PHARMACOVIGILANCE; REPUBLIC OF BELARUS; YOUNG ADULT;

EID: 84939980256     PISSN: 01145916     EISSN: 11791942     Source Type: Journal    
DOI: 10.1007/s40264-015-0279-7     Document Type: Article

References (15)

1. Palella FJ Jr, Delaney KM, Moorman AC, Loveless MO, Fuhre J, Satten GA, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med. 1998;338:853–60.
2. Hogg RS, Yip B, Kully C, Craib KJP, O’Shaughnessy MV, Schechter MT, et al. Improved survival among HIV-infected patients after initiation of triple drug antiretroviral regimens. CMAJ. 1999;160(5):659–65.
3. D’Arminio Monforte A, Lepri AC, Rezza G, et al. Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naive patients. I.CO.N.A. Study Group. Italian Cohort of Antiretroviral-Naive Patients. AIDS. 2000;14:499–507.
4. Bassetti S, Battegay M, Furrer H, et al. Why is highly active antiretroviral therapy (HAART) not prescribed or discontinued? Swiss HIV Cohort Study. J Acquir Immune Defic Syndr. 1999;21:114–9.
5. Wolfe D, Carrieri MP, Shepard D. Treatment and care for injection drug users with HIV infection: a review of barriers and ways forward. Lancet. 2010;376(9738):355–66.
6. The world medicines situation 2011. Pharmacovigilance and safety of medicines. World Health Organization. http://apps.who.int/medicinedocs/documents/s18771en/s18771en.pdf. Accessed 18 Dec 2014.
7. Monitoring Medicines Project. http://www.monitoringmedicines.org. Accessed 18 Dec 2014.
8. The Uppsala Monitoring Centre. The use of WHO-UMC system for standardized case causality assessment. Available at: http://who-umc.org/Graphics/24734.pdf. Accessed 18 Dec 2014.
9. A practical handbook on the pharmacovigilance of antiretroviral medicines. Geneva: World Health Organization; 2009. http://apps.who.int/medicinedocs/documents/s16882e/s16882e.pdf. Accessed 18 Dec 2014.
10. The safety of medicines in public health programmes: pharmacovigilance an essential tool. Geneva: World Health Organization; 2006. http://www.who.int/medicines/areas/quality_safety/safety_efficacy/Pharmacovigilance_B.pdf. Accessed 18 Dec 2014.
11. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection. Recommendations for a public health approach. Geneva: World Health Organization; 2013.
12. U.S. National Institutes of Health. Common Terminology Criteria for Adverse Events (CTCAE) v.4.0. http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm. Accessed 18 Dec 2014.
13. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharacol Ther. 1981;30:239–45.
14. Post-approval safety data management: definitions and standards for expedited reporting. E2D. ICH Harmonised Tripartite Guideline. Version 4. 12 November 2003. http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E2D/Step4/E2D_Guideline.pdf. Accessed 27 Feb 2015.
15. Guidelines for preparing core clinical-safety information on drugs. Report of CIOMS Working Group III. Geneva: CIOMS; 1994.